在较高度下,局部洛萨坦剂量反应和角膜毒性
Barbara Araujo Lima Dutra1,2, Valeria Villabona Martinez1, Marcony R Santhiago2
1Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; and.
Cornea
|October 23, 2024
概括
高剂量的局部洛萨坦 (8毫克/毫升) 在子性烧伤中加剧了角膜纤维化和毒性. 较低剂量 (0.8 mg/mL) 耐受性更好,不透明度降低,这表明要谨慎使用局部洛萨坦.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 再生医学是一种再生医学.
背景情况:
- 性烧伤会导致角膜层纤维化.
- 局部药物用于管理眼睛表面疾病.
- 洛沙坦是一种血管激素II受体阻断剂,已显示出抗纤维素的特性.
研究的目的:
- 评估不同度局部洛萨坦在子模型中引起的角膜纤维化的疗效和安全性.
- 确定局部洛萨坦的最佳剂量,以控制角膜纤维化,同时最大限度地减少眼睛表面的毒性.
主要方法:
- 在18只子眼中引起了标准化的性烧伤.
- 眼睛接受了局部洛萨坦0.8毫克/毫升,8毫克/毫升或40毫克/毫升的治疗,每天六次.
- 评价了角膜不透明度,上皮缺陷和纤维化标志物 (阿尔法平滑肌动蛋白,维丁).
主要成果:
- 40 mg/mL 洛萨坦组显示严重的眼表面毒性,并停止了治疗.
- 8毫克/毫升洛萨坦组表现出持续的上皮缺陷和显著的树皮不透明性.
- 0.8 mg/mL 洛萨坦组显示角膜不透明度降低,耐受性更好,尽管一只眼睛有持续的缺陷.
结论:
- 局部洛萨坦度超过0.8 mg/mL应谨慎使用,因为潜在的眼睛表面毒性.
- 对于上皮缺陷的眼睛,建议使用0.2mg/ml洛萨坦的较低度,直到愈合发生.
相关概念视频
Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
592
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
592
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Heart Failure Drugs: Diuretics
346
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
346
Antihypertensive Drugs: Potassium-Sparing Diuretics
464
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
464


